NCT03902496 is a NA clinical trial of HIT-6 Questionnaire in Migraine, sponsored by Avulux, Inc..

Who is sponsoring NCT03902496?

NCT03902496 is sponsored by Avulux, Inc..

What drugs are being tested in NCT03902496?

Interventions in NCT03902496: HIT-6 Questionnaire, Avulux Spectacles, Sham Spectacles.

Is NCT03902496 still recruiting?

NCT03902496 is currently completed. Last updated 5 July 2019.

Last reviewed 2019-07-05 · How we verify

NCT03902496

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optical Treatment of Migraines Using the Avulux™ Optical Filter in the Form of Spectacle Lenses.

Completed NA Last updated 5 July 2019

What this trial tests

NA trial testing HIT-6 Questionnaire in Migraine in 60 participants. Completed in 17 May 2019.

Timeline

18 March 2019

Primary endpoint
17 May 2019

17 May 2019

Quick facts

Lead sponsor	Avulux, Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	60
Start date	18 March 2019
Primary completion	17 May 2019
Estimated completion	17 May 2019
Sites	1 location across United States

Drugs / interventions tested

HIT-6 Questionnaire
Avulux Spectacles
Sham Spectacles

Conditions studied

Migraine — all drugs for Migraine →

Sponsor

Avulux, Inc.

Who can join

18 and older, any sex, with Migraine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to evaluate the efficacy of the Avulux device in reducing the impact of migraine headaches as measured by improvement in Headache Impact Test (HIT-6TM) scores at three weeks when compared to a control/sham device.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Migraine

Currently open trials in the same condition.

NCT07419607 — MIGRAFIT: Evaluating a Group Therapy Program Combining Physical Activity, Progressive Muscle Relaxation and Psychoeducat · NA · recruiting
NCT07487701 — Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study · NA · active not recruiting
NCT07343427 — Impact of GON PRF on Central Sensitization in Migraine Patients · NA · active not recruiting
NCT07336056 — Nerivio Efficacy Under High-Frequency Use · Phase 4 · active not recruiting
NCT07385755 — Desvenlafaxine for Preventive Treatment of Frequent Migraines · NA · active not recruiting

Other Avulux, Inc. trials

Trials by the same sponsor.

NCT04341298 — Use of the Avulux® Lenses as an Aid in Reducing the Impact of Migraine Headaches · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03902496 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Avulux, Inc.
Last refreshed: 5 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03902496.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing